Stockscreener 앱 받기
16.11
13.53%
-2.52
시장 영업 전:
16.50
0.39
+2.42%
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
Oppenheimer reiterates Outperform on BioAge Labs stock at $60 By Investing.com - Investing.com India
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress By Investing.com - Investing.com India
Chipmakers Recap: Can BioAge Labs Inc lead its sector in growth2026 WrapUp & Technical Confirmation Alerts - baoquankhu1.vn
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress - Investing.com
BioAge Labs (NASDAQ: BIOA) registers shelf for future equity and debt offers - Stock Titan
BioAge Labs Full-Year 2025 Net Loss Narrows - Moomoo
BioAge Labs (NASDAQ:BIOA) Stock Price Down 9.8%Here's Why - MarketBeat
BioAge Labs Provides Business Updates - Lifespan Research Institute
BioAge Labs Reports Positive 2025 Financial Results and Advances BGE-102 NLRP3 Inhibitor Toward Phase 2 Trials in Cardiovascular and Ophthalmology Indications - Minichart
BioAge Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BioAge Labs 2025-2026 Pipeline: Advancing BGE-102 NLRP3 Inhibitor for Cardiometabolic Disease and Ophthalmology Based on Aging Biology Insights - Minichart
BioAge Highlights BGE-102 Progress and Financial Strength - TipRanks
BIOAGE Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioAge Labs (NASDAQ: BIOA) boosts R&D and outlines cash runway to 2029 - Stock Titan
Earnings Flash (BIOA) BioAge Labs Posts 2025 Collaboration Revenue $9M, vs. FactSet Est of $7.1M - marketscreener.com
Earnings Flash (BIOA) BioAge Labs Posts 2025 Net Loss $2.24 a Share, vs. FactSet Est of $1.89 Loss - marketscreener.com
BioAge Labs (NASDAQ: BIOA) widens 2025 loss but extends cash runway to 2029 - Stock Titan
BioAge says oral drug cut a heart-risk marker 86% in Phase 1 - Stock Titan
BioAge Labs, Inc.(NasdaqGS: BIOA) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Certain Warrant of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
Certain Common Stock of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
BioAge Labs, Inc.: Fundamental Analysis and Financial Ratings | Y7G | US09077V1008 - marketscreener.com
If You Invested $1,000 in BioAge Labs Inc. (BIOA) - Stock Titan
Jefferies upgrades BioAge Labs (BIOA) - MSN
BioAge Labs (NASDAQ:BIOA) Trading Down 5.9%What's Next? - MarketBeat
BioAge Makes a Comeback, Yet Technical Indicators Lean Bearish - Bitget
Can BioAge Labs Inc expand its profit marginsMarket Performance Summary & Pattern Based Trade Signal System - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Up 8.8%Should You Buy? - MarketBeat
BIOAGE Labs Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
BioAge Labs, Inc. (NASDAQ:BIOA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quarterly Recap: Will BioAge Labs Inc outperform small cap indexesTrade Volume Summary & Daily Entry Point Alerts - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Given New $52.00 Price Target at Citigroup - MarketBeat
Aug Update: Will BioAge Labs Inc outperform small cap indexesEarnings Recap Report & Smart Swing Trading Techniques - baoquankhu1.vn
Bioage Labs Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
BioAge Labs (BIOA) price target increased by 24.14% to 12.24 - MSN
Market Trends: How does BioAge Labs Inc perform in inflationary periodsTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn
BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit - Law360
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 7,433 shares in 10b5-1 trade - Stock Titan
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs (NASDAQ:BIOA) Shares Gap DownHere's Why - MarketBeat
BIOA (NASDAQ: BIOA) insider files Form 144 showing multiple sales - Stock Titan
Risk Analysis: How does BioAge Labs Inc perform in inflationary periods2025 Performance Recap & Community Driven Trade Alerts - baoquankhu1.vn
Investment Recap: How do insiders feel about BioAge Labs Inc2025 Geopolitical Influence & Weekly High Return Stock Opportunities - baoquankhu1.vn
BIOA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion - Yahoo Finance
Oppenheimer Begins Coverage on BioAge Labs (NASDAQ:BIOA) - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Oppenheimer Initiates Coverage of BioAge Labs (BIOA) with Outperform Recommendation - Nasdaq
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal - TipRanks
BioAge Labs (BIOA) Price Target Increased by 10.09% to 30.60 - Nasdaq
Oppenheimer initiates BioAge Labs stock coverage with outperform rating - Investing.com Nigeria
Oppenheimer initiates BioAge Labs stock coverage with outperform rating By Investing.com - Investing.com Canada
Technical Analysis: Is BioAge Labs Inc backed by strong institutional buyingQuarterly Portfolio Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Fed Watch: Whats the beta of BioAge Labs Inc stock2025 Market Sentiment & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
BioAge Labs, Inc. (BIOA) Receives Buy Rating From Jefferies With Significant Upside Potential - 富途牛牛
Jefferies upgrades BioAge Labs stock rating on drug potential By Investing.com - Investing.com Nigeria
1.75%
1.88%
자본화:
|
볼륨(24시간):